County Bk Greenwood S C Com COYA 深 沪
等待开盘 10-31 09:30:00 美东时间
6.12
-0.170
-2.70%
华盛通- 最 高6.41
- 今 开6.25
- 成交量 17.09万股
- 最 低 6.07
- 昨 收 6.29
- 总市值 1.02亿
- 52周最高 8.29
- 市盈率 静 --
- 换手率 1.02%
- 52周最低 4.65
- 委 比 -92.45%
- 总股本 1674.26万
- 历史最高 10.6899
- 量 比 0.43
- 振 幅 5.41%
- 历史最低 3.21
- 每 手 1
- 风险率 0.57%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多AI这笔账算不过来！“老价投”绿光资本艾因霍恩最新持有人信：我们决定不参与这波过热的狂欢
炒股就看金麒麟分析师研报，权威，专业，及时，全面，助您挖掘潜力主题机会！ 来源：聪明投资者 在这个由AI主导叙事的时代，绿光资本（Gre...
10-30 15:07
Coya Therapeutics shares are trading lower after the company announced a proposed public offering of common stock.
Coya Therapeutics shares are trading lower after the company announced a propos...
10-24 04:59
对冲基金大佬对AI热潮“敬而远之”，更青睐这项技术……
①绿光资本创始人大卫·艾因霍恩对人工智能投资热潮发出警告，称其公司目前对人工智能敬而远之，并表示不能理解当前在这一领域的庞大投资数量； ②艾因霍恩认为，在这个生态系统之外的长期投资中赚钱变得更加困难，但他并不后悔，并表示更愿意投资于生物技术公司Coya Therapeutics。
10-23 15:37
Coya Therapeutics jumps as Greenlight discusses in Q3 letter
Coya Therapeutics (NASDAQ:COYA) surged 17% after David Einhorn's Greenlight hedge fund disclosed it's the company's largest holder in its lastest Q3 letter to investors. Coya's lead drug is aimed at t...
10-14 23:09
美股大行评级 | 潜在涨幅超31%！摩根大通维持通用汽车"超配"评级，目标价从60美元升至80美元
今日重点评级关注：Maxim Group：上调Adial Pharmaceuticals评级至"买入"，目标价1.5美元；BTIG：维持Climb Bio"买入"评级，目标价从7美元升至8美元
10-01 20:13
Coya Therapeutics Completes Patient Enrollment Of Investigator-Initiated, Open-Label Study With Low-Dose IL-2 And CTLA4-Ig Combination Treatment In Patients With Mild To Moderate Frontotemporal Dementia
Following the positive interim results in 5 patients announced earlier this year, a total of 9 patients have been enrolled as plannedThe study is progressing according to protocol, and no safety issues have been
09-29 20:20
EXCLUSIVE: Coya Therapeutics Investigational Combination Therapy With GLP-1 Shows Potential For Alzheimer's Disease
Coya's COYA 303 showed strong immune modulation and reduced inflammation in the brain, supporting its development for neurodegenerative diseases like Alzheimer's.
09-16 19:45
Coya Therapeutics' Upcoming Phase 2 Clinical Trial To Evaluate Efficacy And Safety Of COYA 302 In Patients With ALS Accepted As NEALS-Affiliated Trial By NEALS Consortium
NEALS, the world's largest ALS research consortium, has selected the COYA 302 trial and it is now affiliated with NEALS as part of its mission to accelerate the development of new treatments for people living with
09-04 20:14
What's Going On With Coya Therapeutics Stock?
Shares of Coya Therapeutics are trading higher Monday morning. The company provided an update regarding the development of a new treatment for Amyotrophic Lateral Sclerosis.
08-25 21:57
HC Wainwright & Co. Reiterates Buy on Coya Therapeutics, Maintains $18 Price Target
HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Coya Therapeutics (NASDAQ:COYA) with a Buy and maintains $18 price target.
08-25 19:25
